Roche shares rise as company advances experimental obesity drug to late-stage trial
Editorial & Advertiser disclosure
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Headlines
Written By Global Banking and Finance Review
Posted on September 22, 2025
(Reuters) -Shares in Roche Holding rose around 2% on Monday, outperforming a broadly unchanged European healthcare index, as the drugmaker said it was advancing its experimental obesity drug CT-388 to a late-stage clinical trial.
Roche acquired this drug candidate in late 2023 when it acquired U.S. biotech firm Carmot Therapeutics in its first major bid to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly. Roche shares jumped nearly 5% when it reported results from an early-stage trial of this drug showing it led to significant weight loss.
The Swiss drugmaker was presenting an update on its obesity drugs pipeline at an investor day in London. Roche’s pharmaceutical division head Teresa Graham told investors that the company aims to become a major player in the lucrative obesity drug market and plans to secure a strong entry to this market with competitive products by 2030.
“Our goal is to become a Top 3 player (in the obesity drug market), and I want you to know I’m serious about this goal,” Teresa Graham, the head of Roche’s pharmaceutical division, told investors, saying that Roche had a track record of successfully moving into new therapeutic areas with competitive drugs that became blockbusters.
(Reporting by Maggie Fick; editing by Danilo Masoni and Louise Heavens)
Credit: Source link
